<DOC>
	<DOCNO>NCT01127139</DOCNO>
	<brief_summary>The fixed combination verapamil SR/trandolapril ( Tarka® ) effective , well-tolerated therapy treatment essential hypertension require one agent achieve optimal blood pressure ( BP ) control . The endpoint compliance Tarka® treatment number/percentage patient continue fixed combination Tarka therapy six month . This Post Marketing Observational Study conduct prospective , single-arm , single-country , multicenter format . The investigational site cardiologist , doctor internal medicine general practician . Since Post Marketing Observational Study , Tarka® prescribe usual manner accordance term local market authorization regard dose , population indication well local guideline .</brief_summary>
	<brief_title>Effectiveness Patient Self-assessed Compliance Blood Pressure Treatment With Tarka® Fixed Combination Patients With Essential Hypertension</brief_title>
	<detailed_description>Follow-up patient enable 4 patient visit period . For reason , likely visit define `` Inclusion visit '' treatment Tarka® initiate , `` Follow-up visit Week 4-6 '' , `` Follow-up visit Month 3 `` `` Follow-up visit Month 6 '' , although date depend decision physician . For reason , likely visit define `` S/V '' ( Screening Visit ) , `` F1 '' ( Follow-up 1 ) , `` F2 '' ( Follow-up 2 ) , `` F3 '' ( Follow-up 3 ) . The end point compliance Tarka® treatment number/percentage patient continue fixed combination Tarka therapy six month .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Men , woman 18 year Patients uncontrolled essential hypertension eligible Tarka treatment accord local label ( BP ≥ 140/90 mmHg ) Patients provide oral informed consent ( include consent medical data use Post Marketing Observational Study ) cooperate physician Patients never receive Tarka® past Patients Tarka® prescribe accord label indication dose Patients contraindicate treatment Tarka® accord local Summary Product Characteristics ( SmPC ) : Hypersensitive active substance inactive ingredient With cardiogenic shock With second third degree atrioventricular block except patient function artificial pacemaker With sick sinus syndrome except patient function artificial pacemaker With atrial fibrillation/flutter concomitant WolffParkinsonWhite syndrome With exist history angioedema associate administration ACE inhibitor With severe renal ( creatinine clearance &lt; 10 ml/min ) severe liver impairment ( cirrhosis ascites ) Pregnant woman , woman childbearing potential unwilling use contraception Lactating woman Patients participate clinical study within last month currently enrol clinical study Patients currently treat fix antihypertensive combination</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Essential hypertension</keyword>
</DOC>